Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Mesothelioma 21Mesothelioma, Malignant 18Advanced Solid Tumor 17Carcinoma, Non-Small-Cell Lung 15Solid Tumor 14Advanced Solid Tumors 13Melanoma 12Esophageal Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Uterine Cervical Neoplasms 8Solid Tumors 8Ovarian Neoplasms 8Solid Tumor, Adult 7Neoplasm Metastasis 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6Breast Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Endometrial Neoplasms 5Cholangiocarcinoma 5Neoplasms 4Locally Advanced or Metastatic Solid Tumors 4Head and Neck Neoplasms 4Advanced or Metastatic Solid Tumors 4Urinary Bladder Neoplasms 3Solid Tumor Malignancies 3

Interventions

pembrolizumab 4toripalimab 2tislelizumab 1spartalizumab 1sintilimab 1efineptakin alfa 1camrelizumab 1atezolizumab 1Taxes 1MK 2206 1Injections 1Cyclophosphamide 1Cetuximab 1Albumin-Bound Paclitaxel 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × pembrolizumab × Other solid neoplasm × Clear all
NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05205109 2025-06-09

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Antengene Corporation

Phase 1 Recruiting
98 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT06293651 2025-02-12

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Dong-A ST Co., Ltd.

Phase 1/2 Recruiting
125 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT04564417 2024-01-31

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Pierre Fabre Medicament

Phase 1 Terminated
33 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡